Evidence map›Paper›PMID 36351818›Full record

ArticleeNeuro

Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson's Disease.

Sangita Paul, Saman Fatihi, Srishti Sharma, Rintu Kutum, Raymond Fields, Harish C Pant, Lipi Thukral, Binukumar Bk

Open access · goldAbstract read
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sangita PaulCouncil of Scientific and Industrial Research-Institute of Genomics and Integrative Biology, New Delhi 110007, India.
Saman FatihiCouncil of Scientific and Industrial Research-Institute of Genomics and Integrative Biology, New Delhi 110007, India.
Srishti SharmaCouncil of Scientific and Industrial Research-Institute of Genomics and Integrative Biology, New Delhi 110007, India.
Rintu KutumCouncil of Scientific and Industrial Research-Institute of Genomics and Integrative Biology, New Delhi 110007, India.ORCID https://orcid.org/0000-0001-8667-6199
Raymond FieldsViral Production Core Facility, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Harish C PantNeuronal Cytoskeletal Protein Regulation Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Lipi ThukralCouncil of Scientific and Industrial Research-Institute of Genomics and Integrative Biology, New Delhi 110007, India.
Binukumar BkCouncil of Scientific and Industrial Research-Institute of Genomics and Integrative Biology, New Delhi 110007, India binukumarbk@gmail.com.
Institute of Genomics and Integrative Biology · INNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperactivation of cyclin-dependent kinase 5 (Cdk5) by p25, contributes to neuroinflammation causing neurodegeneration in Parkinson's disease (PD) and Alzheimer's disease. However, the mechanism by which Cdk5 induces neuroinflammation in the PD brain is largely unexplored. Here, we show that Cdk5 phosphorylates cytosolic phospholipase A2 (cPLA2) at Thr-268 and Ser-505 sites lead to its activation and generation of eicosanoid products. Mutational studies using site-directed mutagenesis and molecular simulations show that the architecture of the protein changes on each single-point mutation. Interestingly, double mutations also led to a severe decline in the activity of cPLA2 and to the disruption of its translocation to the plasma membrane. Further, the brain lysates of transgenic PD mouse models show hyperactivation of Cdk5, resulting in enhanced phosphorylation of Thr-268 and Ser-505 of cPLA2 and its heightened activity, confirming the findings observed in the cell culture model of PD. These phosphorylation sites of cPLA2 and Cdk5 could be explored as the future therapeutic targets against neuroinflammation in PD. Further, conjoint transcriptomic analysis of the publicly available human PD datasets strengthens the hypothesis that genes of the arachidonic acid, prostaglandin synthesis, and inflammatory pathways are significantly upregulated in the case of PD patients compared with that of healthy control subjects.

Indexed as

Cyclin-Dependent Kinase 5Parkinson DiseasePhospholipases A2, CytosolicAnimalsHumansMiceMice, TransgenicNeuroinflammatory DiseasesPhosphorylationCDK5 protein, humanCyclin-Dependent Kinase 5Phospholipases A2, CytosolicCdk5cPLA2neuroinflammationParkinson’s disease

Identifiers

PMID36351818
PMCPMC9698719
OpenAlexW4308623277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.